A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors

被引：0
|
作者：
Saura, Cristina
Jones, Suzanne
Mateo, Joaquin
Hollebecque, Antoine
Cleary, James M.
Perez, Desamparados Roda
Zhu, Jin
Musib, Luna C.
Patel, Premal H.
Cervantes-Ruiperez, Andres
Isakoff, Steven J.
Soria, Jean-Charles
Molife, L. Rhoda
Tabernero, Josep
Bendell, Johanna C.
机构：
[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Royal Marsden Hosp, Surrey, England
[4] Inst Canc Res, Surrey, England
[5] Inst Gustave Roussy, Villejuif, France
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Hosp Clin, Dept Med Oncol, Colorectal Unit, Dept Surg, Valencia, Spain
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] Univ Valencia, Dept Hematol & Med Oncol, INCLIVA, Valencia, Spain
[10] Massachusetts Gen Hosp, Boston, MA 02114 USA
[11] Sarah Cannon Res Inst Tennessee Oncol PLLC, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3021
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I clinical and pharmacokinetic (PK) study of paclitaxel (P) and docetaxel (D) in patients (PTS) with solid tumors.
    Izquierdo, MA
    Pontón, JL
    García, M
    Navarro, M
    Mesia, R
    Cardenal, F
    Gil, M
    Germá, JR
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S84 - S84
  • [42] A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs)
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    VerMeulen, W.
    Harper, K.
    Liu, G.
    Tye, L.
    Chao, R.
    Traynor, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Phase Ib trial of ATR inhibitor (ATRi) tuvusertib plus ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors
    Siu, Lillian L.
    Cabanas, Elena Garralda
    Boni, Valentina
    Tolcher, Anthony W.
    Garcia, Enrique Sanz
    Fuentes-Antras, Jesus
    Saavedra, Omar
    Vagge, Deepthi S.
    Locatelli, Giuseppe
    Gunhan, Burak Kursad
    Pennock, Gregory
    Mukker, Jatinder Kaur
    Gounaris, Ioannis
    Yap, Timothy A.
    CANCER RESEARCH, 2024, 84 (07)
  • [44] Phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs)
    Traynor, A. M.
    Sandler, A. B.
    Schiller, J. H.
    Ilagan, J.
    Vermeulen, W. L.
    Liu, G.
    Tye, L.
    Verkh, L.
    Chao, R.
    Robert, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] A phase I study of the heparanase inhibitor: PI-88 and weekly docetaxel in patients (PTS) with advanced solid malignancies.
    Raj, SKS
    Basche, M
    Gore, L
    Grolnic, S
    Hunt, J
    O'Bryant, CL
    Morrow, M
    Creese, B
    Kangas, M
    Sawlwin, D
    Eckhardt, SG
    Holden, SN
    Holden, SN
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6152S - 6152S
  • [46] A phase Ib trial of ERK inhibition with ulixertinib combined with palbociclib in patients (Pts) with advanced solid tumors.
    Raybould, Alison L.
    Burgess, Brian
    Urban, Clarissa
    Naim, Rashid
    Lee, Michael Sangmin
    McRee, Autumn Jackson
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Final results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.
    Eskens, Ferry
    Oldenhuis, Corina N.
    Loos, Walter J.
    Esteves, Brooke
    van Doorn, Leni
    Cotreau, Monette M.
    Bhargava, Pankaj
    Zhang, Joshua
    Strahs, Andrew Louis
    den Hollander, Martha Willemine
    Gietema, Jourik A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours
    Fu, S.
    Hong, D.
    Fogelman, D.
    Shaikh, F.
    Dupont-Roettger, D.
    Bisdas, S.
    Dumbrava, E. E. Ileana
    Piha-Paul, S.
    Liu, L.
    Dugourd, D.
    Yamamura, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S499 - S500
  • [49] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
    Gerald S Falchook
    Jasgit Sachdev
    Esteban Rodrigo Imedio
    Sanjeev Kumar
    Ganesh M Mugundu
    Suzanne Jenkins
    Juliann Chmielecki
    Suzanne Jones
    David R Spigel
    Melissa Johnson
    Investigational New Drugs, 2023, 41 : 493 - 502
  • [50] Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine (gem) in patients (pts) with refractory solid tumors
    Italiano, A.
    Infante, J. R.
    Shapiro, G.
    Moore, K. N.
    Lorusso, P.
    Postel-Vinay, S.
    Cousin, S.
    Toulmonde, M.
    Lucchesi, C.
    Blackwood, E.
    Mahrus, S.
    Lu, X.
    Tagen, M.
    Schutzman, J.
    Lauchle, J.
    Soria, J-C.
    ANNALS OF ONCOLOGY, 2017, 28
12345